Tiziana Life Sciences Files Investigational New Drug Application with FDA for ALS Phase 2 Clinical Trial
Ivor Elrifi, CEO of Tiziana Life Sciences, expressed enthusiasm about this milestone, stating, "We are excited to initiate this important clinical study with the support of the ALS Association grant.
Pharm Exec4d
FDA Approves Investigational New Drug Application for Fapon Biopharma’s Novel Immunotherapy for Solid Tumors
FP008 is designed for patients with solid tumors that have not responded to existing immunotherapies targeting PD-1.
Hosted on MSN1d
AZTR: Netherton Topline Expected by Year-End
AZTR READ THE FULL AZTR RESEARCH REPORT Azitra, Inc. (NYSE:AZTR) reported 2024 results in a February press release ...
Targeted Oncology4d
FDA Clears IND for Phase 1 Trial of ADCE-T02 in Solid Tumors
The FDA approved the investigational new drug application for a phase 1 trial of ADCE-T02 in advanced solid tumors.
Healio11d
FDA clears investigational new drug application for Zabalafin Hydrogel
The investigational new drug application for Zabalafin Hydrogel for the treatment of mild to moderate atopic dermatitis has ...
GlobalData on MSN8d
DeFloria launches Phase II ASD irritability cannabis therapy trial
The Phase II trial comes as the US Food and Drug Administration grants an investigational new drug application for cannabis ...
Targeted Oncology8d
FDA Clears IND Application for LTZ-301 in non-Hodgkin Lymphoma
The FDA cleared the investigational new drug application for LTZ-301, a first-in-class myeloid engager immunotherapy, with a ...
manilatimes8h
Quoin Pharmaceuticals Files U.S. and International Patent Applications for Novel Topical Rapamycin Formulations to Treat Rare Disease Indications
Proprietary Invisicare Delivery Technology Designed to Optimize Local Skin Penetration The proprietary Invisicare delivery technology, which Quoin has exclusive rights to for all orphan rare skin ...
Morningstar13d
Alphyn Secures FDA Clearance of Investigational New Drug Application for Atopic Dermatitis Treatment
Zabalafin Hydrogel is a novel, first-in-class complex single-source botanical drug with multiple bioactive compounds that provide multiple mechanisms of action, including anti-pruritic (anti-itch ...
manilatimes4d
AIM announces Paul Goepfert, MD, as the principal investigator for the planned clinical study of Ampligen and FluMist as a vaccine for avian influenza
Paul Goepfert, MD, Director for the Alabama Vaccine Research Clinic, stated: "I'm excited for the opportunity to follow-up on ...